Patent · US Active

Engineered chimeric fusion protein compositions and methods of use thereof

US12030938B2 · kind B2 · utility

0Cited by

46References

30Claims

0Family size

Assignee

MYELOID THERAPEUTICS, INC. · US

Inventors

Daniel R. Getts · Evanston, US
Yuxiao Wang · Belmont, US

Key dates

Filing date	Jan 20, 2023
Grant date	Jul 9, 2024
Priority date	—
Expiry date	Jan 20, 2043

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/70
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Compositions and methods for making and using engineered cells, such as, engineered myeloid cells that express a chimeric fusion protein that has a binding domain capable to binding surface molecules on target cells such as diseased cells.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.